{"id":"azd4144","safety":{"commonSideEffects":[{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these enzymes, AZD4144 is thought to modulate immune cell function and potentially treat various conditions. However, the exact mechanism of action is still being researched.","oneSentence":"AZD4144 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:57:41.553Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory chronic lymphocytic leukemia (CLL)"}]},"trialDetails":[{"nctId":"NCT07215702","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-10","conditions":"Sepsis, Acute Kidney Injury","enrollment":124},{"nctId":"NCT06675175","phase":"PHASE1","title":"A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-12-09","conditions":"Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease","enrollment":29},{"nctId":"NCT06942923","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-04-22","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT06693765","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-11-18","conditions":"Renal Impairment, End-stage Kidney Disease, Healthy Participants","enrollment":41},{"nctId":"NCT06948006","phase":"PHASE1","title":"A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-04-23","conditions":"Healthy Participants","enrollment":32},{"nctId":"NCT06491550","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-07-15","conditions":"Healthy Participants","enrollment":91},{"nctId":"NCT06925854","phase":"PHASE1","title":"A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-04-17","conditions":"Healthy","enrollment":12},{"nctId":"NCT06122714","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-11-07","conditions":"Healthy Participants","enrollment":95}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AZD4144","genericName":"AZD4144","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD4144 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}